Modulation of disease severity in mice with targeted disruption of the acid α-glucosidase gene

Nina Raben, Kanneboyina Nagaraju, Eunice Lee, Paul Plotz

Research output: Contribution to journalArticlepeer-review

Abstract

Glycogen storage disease type II (GSDII) is a recessively inherited disorder caused by defects in lysosomal acid α-glucosidase. In an attempt to reproduce the range of clinical manifestations of the human illness we have created null alleles at the acid α-glucosidase locus (GAA) with several gene targeting strategies. In each knockout strain, enzyme activity was completely abolished and glycogen accumulated at indistinguishable rates. The phenotypes, however, differed strikingly. Acid α-glucosidase deficiency on a 129 x C57BL/6 background resulted in a severe phenotype with progressive cardiomyopathy and profound muscle wasting similar to that in patients with glycogen storage disease type II. On a 129/C57BL/6 x FVB background, homozygous mutants developed a milder phenotype with a later age of onset. Females were more affected than males irrespective of genetic background. As in humans with glycogen storage disease type II, therefore, other genetic loci affect the phenotypic expression of a single gene mutation. (C) 2000 Published by Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)283-291
Number of pages9
JournalNeuromuscular Disorders
Volume10
Issue number4-5
DOIs
StatePublished - Jun 1 2000
Externally publishedYes

Keywords

  • Acid α-glucosidase
  • Gene targeting
  • Glycogen storage disease type II
  • Phenotype

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Fingerprint

Dive into the research topics of 'Modulation of disease severity in mice with targeted disruption of the acid α-glucosidase gene'. Together they form a unique fingerprint.

Cite this